NAS:CNCR

Range Cancer Therapeutics ETF

$ 9.02 0 ( +0%) 01:44 PM EST
PE Ratio:
37.64
PB Ratio:
1.31
Volume:
-
Dividend Yield %:
0
Last Holding update 2025-06-17 75 Stocks (0 new)
Value $9.00 Mil Turnover 0 %
Top Holdings: RXRX(4.04%) PGEN(3.07%) CMPX(3.01%) GNLX(2.92%) SWTX(2.88%)
Portfolio Report
Registrant: Range Cancer Therapeutics ETF
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Performance Chart Fundamental Charts Technical Indicators Gurus Trades Top Holdings Sector Breakdowns Holding History Back to Top

Range Cancer Therapeutics ETF Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Range Cancer Therapeutics ETF Key Statistics

Name Value
Day's Open ($) 9.02
Day's Range ($) 9.02 - 9.02
Day's Volume
52-Week Range ($) 7.881 - 16.27
Beta 1.08
3-Year Sharpe Ratio -0.52
3-Year Sortino Ratio -0.73
Volatility 29.13
14-Day RSI 46.33
14-Day ATR ($) 0.178627
20-Day SMA ($) 8.949

Fundamental Data

Name Value
Market Cap (Mil $) -
Shares Outstanding (Mil) 0.78
PE Ratio 37.64
PE Ratio (10y Range) 12.64 - 37.64
PE Ratio (10y Median) 20.85
PB Ratio 1.31
PB Ratio (10y Range) 1.31 - 5.84
PB Ratio (10y Median) 3.84

Dividend Data

Name Value
Dividends per Share (TTM) ($) -
Dividend Yield % -
Dividend Yield % (10y Range) 0.4 - 14.16
Dividend Yield % (10y Median) 1.31
Next Dividend Payment Date
Dividend Frequency -

CNCR Range Cancer Therapeutics ETF Fundamental Charts

Historical TTM Price-to-Earnings for CNCR Range Cancer Therapeutics ETF

Historical TTM Price-to-Earnings without NRI for CNCR Range Cancer Therapeutics ETF

Historical Price-to-Book Ratio for CNCR Range Cancer Therapeutics ETF

Historical Dividend Yields for CNCR Range Cancer Therapeutics ETF

Range Cancer Therapeutics ETF Technical Indicators

Moving Average

Momentum

Gurus Latest Trades with NAS:CNCR

No Available Data

NAS:CNCR is held by these investors

No Available Data
Range Cancer Therapeutics ETF Top Holdings of 2025-02-28 View Full List
Ticker
Company
Shares
Value ($1000)
Shares Change %
Weighting %
Trade Impact %
% of Shares outstanding
3M Change %
YTD Change %
Market Cap $Mil
Industry
RXRX
Recursion Pharmaceuticals Inc
47,707
358.3
-6.02%
4.040
-0.18%
0.010
+9.91%
-6.51%
2,740.2
Biotechnology
PGEN
Precigen Inc
157,416
272.3
-6.02%
3.070
-0.08%
0.050
+3.14%
+46.43%
484.1
Biotechnology
CMPX
Compass Therapeutics Inc
92,038
266.9
-6.02%
3.010
-0.08%
0.070
+51.89%
+122.07%
445.3
Biotechnology
GNLX
Genelux Corp
61,963
259.0
-6.02%
2.920
-0.09%
0.160
+14.47%
+50.85%
134.4
Biotechnology
SWTX
SpringWorks Therapeutics Inc
4,426
255.7
-6.01%
2.880
-0.10%
0.010
+1.01%
+30.06%
3,540.6
Biotechnology
EXEL
Exelixis Inc
5,730
221.7
-6.00%
2.500
-0.11%
0.000
+20.72%
+34.89%
12,250.1
Biotechnology
DNA
Ginkgo Bioworks Holdings Inc
25,263
208.2
-6.02%
2.350
-0.12%
0.040
+84.43%
+47.81%
849.6
Biotechnology
REPL
Replimune Group Inc
15,047
190.8
-6.01%
2.150
-0.11%
0.020
-64.51%
-73.45%
247.8
Biotechnology
BMY
Bristol-Myers Squibb Co
3,149
187.7
-6.00%
2.120
-0.10%
0.000
+1.85%
-10.39%
99,607.0
Drug Manufacturers
SDGR
Schrodinger Inc
7,925
176.8
-6.01%
1.990
-0.10%
0.010
-13.51%
+17.16%
1,658.3
Healthcare Providers & Services

Range Cancer Therapeutics ETF's Historical Top Holdings Breakdowns

Range Cancer Therapeutics ETF's Top Stock Picks View Full List
Ticker
Company
Date
Action
Impact %
Price Range
Price
Price Change from Avrg%
Comment
Current Shares
Share Change
RXRX
Recursion Pharmaceuticals Inc
2025-02-28
Reduce
Reduce
-0.18%
●
6.03 ($7.56) 10.87
$6.32
-16.40%
Reduce -6.02%
47,707
-3,054
GLUE
Monte Rosa Therapeutics Inc
2025-02-28
Reduce
Reduce
-0.16%
●
5.45 ($6.91) 10.36
$5.67
-18.02%
Reduce -6.02%
28,005
-1,793
DNA
Ginkgo Bioworks Holdings Inc
2025-02-28
Reduce
Reduce
-0.12%
●
8.24 ($11.1) 16.36
$14.52
30.77%
Reduce -6.02%
25,263
-1,617
IBRX
ImmunityBio Inc
2025-02-28
Reduce
Reduce
-0.12%
●
2.32 ($3.24) 5.04
$2.93
-9.57%
Reduce -6.02%
45,097
-2,887
EXEL
Exelixis Inc
2025-02-28
Reduce
Reduce
-0.11%
●
32.38 ($34.69) 38.69
$44.92
29.49%
Reduce -6%
5,730
-366
RVMD
Revolution Medicines Inc
2025-02-28
Reduce
Reduce
-0.11%
●
39.08 ($43.38) 57.85
$37.33
-13.95%
Reduce -6.01%
3,534
-226
REPL
Replimune Group Inc
2025-02-28
Reduce
Reduce
-0.11%
●
10.14 ($12.83) 14.31
$3.21
-74.94%
Reduce -6.01%
15,047
-963
BMY
Bristol-Myers Squibb Co
2025-02-28
Reduce
Reduce
-0.10%
●
53.9 ($57.38) 60.6
$48.95
-14.70%
Reduce -6%
3,149
-201
ZYME
Zymeworks Inc
2025-02-28
Reduce
Reduce
-0.10%
●
12.58 ($14.11) 15.01
$14.03
-0.57%
Reduce -6.01%
12,581
-805
ACLX
Arcellx Inc
2025-02-28
Reduce
Reduce
-0.10%
●
60.26 ($72.26) 95.72
$70.47
-2.47%
Reduce -5.98%
2,045
-130

Range Cancer Therapeutics ETF Total Holding History ($B)

To

Range Cancer Therapeutics ETF's Asset Allocation

To

Range Cancer Therapeutics ETF Past Portfolios

Portfolio Date Number of Stocks New Stocks Total Value ($Mil) Q/Q Turnover

Top Ranked Articles

  • 1

Range Cancer Therapeutics ETF's Hypothetical Growth since 2025-02-28

Range Cancer Therapeutics ETF's Yearly Returns

Year Portfolio % % Excess Gain %

Range Cancer Therapeutics ETF's Holdings Heat Map

Size field:

Range Cancer Therapeutics ETF's Holdings Bubble Chart

Range Cancer Therapeutics ETF News

  • 1

Discussions on Range Cancer Therapeutics ETF

User's Avatar
How would you rate this stock? CNCR
No discussions yet.
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.